NCT00019188CompletedPhase 1
Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Locations
- 1
Study Overview
Brief Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients with AIDS -related Kaposi's sarcoma.
Detailed Description
OBJECTIVES: I. Determine the maximum tolerated dose of interleukin-12 (IL-12) in patients with AIDS-associated Kaposi's sarcoma.
II. Determine the antitumor activity of IL-12 in these patients. III. Determine the effect of IL-12 on angiogenic factors, including basic fibroblast growth factor, vascular endothelial growth factor, and interferon-inducible protein 10 in these patients.
IV. Determine the immunologic and virologic effects of IL-12 in these patients.
PROTOCOL OUTLINE: This is a dose escalation study. Patients receive interleukin-12 (IL-12) subcutaneously twice a week (at least 3 days apart) for 6 months. Patients with stable or better disease continue IL-12 treatment in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Ten additional patients are treated at the MTD.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics-- Histologically proven Kaposi's sarcoma (KS) At least 5 lesions evaluable by noninvasive methods No acutely life threatening lesions that may be responsive to other therapy Actively bleeding or critically located lesions may be excluded at the discretion of the Study Chair or Principal Investigator Asymptomatic pulmonary disease not requiring immediate cytotoxic therapy allowed HIV-associated disease Anti-HIV serum antibodies measured by ELISA and Western blot Stable dose of two or more of the following antiretroviral agents required for 4 weeks prior to study: Lamivudine Didanosine Zidovudine Saquinavir Stavudine Ritonavir Zalcitabine Indinavir Nonnucleoside reverse transcriptase inhibitor Other protease inhibitor Antiretroviral therapy unchanged during study unless medically warranted Patients may switch between antiretroviral agents provided they continue to receive a combination of 2 or more agents --Prior/Concurrent Therapy-- Biologic therapy: At least 6 months since prior interleukin-12 (IL-12) At least 3 weeks since prior interferon therapy At least 2 weeks since prior cytokines or bone marrow stimulating factors (except epoetin alfa) No concurrent cytokines except epoetin alfa or filgrastim (G-CSF) Chemotherapy: At least 3 weeks since prior chemotherapy (at least 6 weeks since prior nitrosoureas or mitomycin) At least 6 months since prior suramin Endocrine therapy: Replacement glucocorticoids allowed At least 2 months since prior systemic glucocorticoids at doses sufficient to affect immune response (e.g., more than 20 mg of prednisone or equivalent for more than 1 week) Radiotherapy: At least 3 weeks since prior radiotherapy Surgery: Not specified Other: See Disease Characteristics At least 3 weeks since prior anti-KS therapy At least 3 weeks since prior local therapy (e.g., intralesional injections) --Patient Characteristics-- Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: Greater than 3 months Hematopoietic: Absolute neutrophil count at least 750/mm3 Platelet count at least 75,000/mm3 Hemoglobin at least 9.0 g/dL (no transfusion within 1 month prior to entry) Hepatic: Bilirubin no greater than 3.7 mg/dL with direct fraction no greater than 0.2 mg/dL and indirect fraction no greater than 3.5 mg/dL AST no greater than 2.5 times upper limit of normal No history of cirrhosis PT/PTT no greater than 120% of control Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 60 mL/min Other: No hypersensitivity to IL-12 or other compounds that crossreact with IL-12 No clinically significant autoimmune disease (e.g., systemic lupus erythematosus) or rheumatologic disease No active, gross gastrointestinal bleeding or uncontrolled peptic ulcer disease No inflammatory bowel disease No severe or life threatening infection with bacterial, viral, fungal, protozoal, or parasitic pathogens within 2 weeks of entry No fever of 39 degrees Celsius or higher within 10 days prior to entry unless underlying infection ruled out No second malignancy within 1 year except: Completely resected basal cell carcinoma Carcinoma in situ of the cervix No generalized debilitation or mental incapacitation that would preclude informed consent No abnormality that would score as a grade 3 toxicity other than lymphopenia or direct manifestations of KS Willing to refrain from unprotected sexual contact and other activities that could result in reinfection with HIV Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 2 months after study
Exclusion Criteria
- Not provided
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the CervixCervical CancerNCT00003017Eastern Cooperative Oncology Group
Completed
Phase 2
Interleukin-12 in Treating Patients With Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00003149Eastern Cooperative Oncology Group40
Completed
Phase 1
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid TumorsMultiple Myeloma and Plasma Cell NeoplasmKidney CancerTesticular Germ Cell TumorGestational Trophoblastic TumorChronic Myeloproliferative DisordersMyelodysplastic SyndromesNeuroblastomaBreast CancerOvarian CancerLymphomaLeukemiaNCT00003107Indiana University
Completed
Phase 1
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterGastrinomaLiver MetastasesLocalized Unresectable Adult Primary Liver CancerLung MetastasesMalignant Pericardial EffusionMetastatic Gastrointestinal Carcinoid TumorMetastatic Parathyroid CancerRecurrent Breast CancerRecurrent Carcinoma of Unknown PrimaryRecurrent Cervical CancerRecurrent Colon CancerRecurrent Endometrial CarcinomaRecurrent Esophageal CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerRecurrent Gastric CancerRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaRecurrent Malignant Testicular Germ Cell TumorRecurrent Squamous Cell Carcinoma of the NasopharynxStage IV Adenoid Cystic Carcinoma of the Oral CavityGlucagonomaAdvanced Adult Primary Liver CancerAnaplastic Thyroid CancerBone MetastasesCarcinoma of the AppendixDistal Urethral CancerFallopian Tube CancerNewly Diagnosed Carcinoma of Unknown PrimaryOccult Non-small Cell Lung CancerPrimary Peritoneal Cavity CancerProximal Urethral CancerPulmonary Carcinoid TumorMale Breast CancerMalignant Pleural EffusionPancreatic Polypeptide TumorInsulinomaInflammatory Breast CancerRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Adrenocortical CarcinomaRecurrent Adult Primary Liver CancerRecurrent Anal CancerRecurrent Bladder CancerRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Non-small Cell Lung CancerRecurrent Ovarian Epithelial CancerRecurrent Pancreatic CancerRecurrent Parathyroid CancerRecurrent Prostate CancerRecurrent Rectal CancerRecurrent Renal Cell CancerRecurrent Salivary Gland CancerRecurrent Small Intestine CancerRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Thyroid CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerRecurrent Vaginal CancerRecurrent Vulvar CancerSkin MetastasesSmall Intestine AdenocarcinomaSomatostatinomaStage III Adenoid Cystic Carcinoma of the Oral CavityStage III Adrenocortical CarcinomaStage III Bladder CancerStage III Cervical CancerStage III Colon CancerStage III Endometrial CarcinomaStage III Esophageal CancerStage III Follicular Thyroid CancerStage III Gastric CancerStage III Malignant Testicular Germ Cell TumorStage III Mucoepidermoid Carcinoma of the Oral CavityStage III Ovarian Epithelial CancerStage III Pancreatic CancerStage III Papillary Thyroid CancerStage III Prostate CancerStage III Rectal CancerStage III Renal Cell CancerStage III Salivary Gland CancerStage III Squamous Cell Carcinoma of the LarynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the NasopharynxStage III Squamous Cell Carcinoma of the OropharynxStage III Vaginal CancerStage III Vulvar CancerStage IIIA Anal CancerStage IIIA Breast CancerStage IIIA Non-small Cell Lung CancerStage IIIB Anal CancerStage IIIB Breast CancerStage IIIB Non-small Cell Lung CancerStage IV Adrenocortical CarcinomaStage IV Anal CancerStage IV Bladder CancerStage IV Breast CancerStage IV Colon CancerStage IV Endometrial CarcinomaStage IV Esophageal CancerStage IV Follicular Thyroid CancerStage IV Gastric CancerStage IV Mucoepidermoid Carcinoma of the Oral CavityStage IV Papillary Thyroid CancerStage IV Prostate CancerStage IV Non-small Cell Lung CancerStage IV Rectal CancerStage IV Ovarian Epithelial CancerStage IV Pancreatic CancerStage IV Renal Cell CancerStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IVA Cervical CancerStage IVA Vaginal CancerStage IVB Cervical CancerStage IVB Vaginal CancerStage IVB Vulvar CancerStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxThyroid Gland Medullary CarcinomaUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerUrethral Cancer Associated With Invasive Bladder CancerWDHA SyndromeNCT00004074National Cancer Institute (NCI)15
Unknown
Phase 1
Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell TransplantationBreast CancerNCT00003412Beth Israel Deaconess Medical Center35